$ USD
¥ 人民币
$ USD
€ 欧元
English
简体中文
English
繁体中文
Sign In / Sign up
Home page
News
Tumor Information
Tumor Information
Tumor medication
Tumor medication
Drug data
Drug data
Tumor medication
Oncology
renal cell carcinoma
cell tumor
solid tumors
IDH1 mutation
non-small cell lung cancer
neurofibromatosis
liposarcoma
neurofibromatosis
Cachexia
bladder cancer
Common Medications
Common medications
Hematology
Hepatobiliary
chronic disease
Endocrinology
Rare disease drugs
Other medications
insomnia
depression
chronic cough
kidney transplant
Drug Classification
Brand Medicine Search
Brand Medicine Search
日本日医工株式会社
日本盐野义制药
日本杏林制药株式会社
日本株式会社
老挝卢修斯
hormone receptor positive
constipate
heart disease
constipate
depression
日本株式会社
日本田边三菱
英国FuturaMedical制药
日本盐野义制药
日本杏林制药株式会社
Medical Q&A
Medical Q&A
About Us
About Us
Menu
Home page
News
Tumor Information
Tumor Information
Tumor medication
Tumor medication
Drug data
Drug data
Tumor medication
Oncology
renal cell carcinoma
cell tumor
solid tumors
IDH1 mutation
non-small cell lung cancer
neurofibromatosis
liposarcoma
neurofibromatosis
Cachexia
bladder cancer
Common Medications
Common medications
Hematology
Hepatobiliary
chronic disease
Endocrinology
Rare disease drugs
Other medications
insomnia
depression
chronic cough
kidney transplant
Drug Classification
Brand Medicine Search
Brand Medicine Search
日本日医工株式会社
日本盐野义制药
日本杏林制药株式会社
日本株式会社
老挝卢修斯
hormone receptor positive
constipate
heart disease
constipate
depression
日本株式会社
日本田边三菱
英国FuturaMedical制药
日本盐野义制药
日本杏林制药株式会社
Medical Q&A
Medical Q&A
About Us
About Us
Home
Oncology
Oncology
Oncology_Medical Halo Global Medical Oncology News_Oncology Drug Therapy News
晚期乳腺癌服用瑞博西林进行治疗的效果
2025-10-19 11:44:20
Check Details
CDK4/6抑制剂瑞博西林多少钱一盒?国内能买到吗?
2025-10-19 11:44:20
Check Details
CDK4/6抑制剂瑞博西利给乳腺癌晚期带来了哪些好处?
2025-10-19 11:44:20
Check Details
瑞博西林是治疗HR+/HER2-绝经后晚期乳腺癌的口服抗癌靶向药
2025-10-19 11:44:20
Check Details
CDK4/6抑制剂瑞博西利治疗乳腺癌晚期的效果显著
2025-10-19 11:44:20
Check Details
奥拉帕利治疗HER2阴性转移性乳腺癌的安全性和耐受性
2025-10-19 11:44:20
Check Details
瑞博西林可有效提高HR+/HER2-绝经前晚期乳腺癌患者生存期
2025-10-19 11:44:20
Check Details
乳腺癌患者服用爱博新进行治疗能活多久?
2025-10-19 11:44:20
Check Details
奥拉帕利可以用于治疗三阴性乳腺癌患者吗?
2025-10-19 11:44:20
Check Details
瑞博西林的出现,使绝经前晚期乳腺癌患者获益
2025-10-19 11:44:20
Check Details
三阴性乳腺癌可以使用爱博新进行治疗吗?
2025-10-19 11:44:20
Check Details
瑞博西林对晚期乳腺癌有着不错的效果
2025-10-19 11:44:20
Check Details
1
2
...
1998
1999
2000
2001
2002
2003
2004
...
4157
4158
Category
Oncology
Hepatobiliary
dermatology
Endocrinology
Hematology
Andrology
Gynecology
Nephrology
Urology
Department of Infectious Diseases
Gastroenterology
Respiratory department
Neurology
Cardiology and Brain Department
ophthalmology
Psychiatry
Immunology Department
orthopedics
Burn Department
相关知识
1
Cabozantinib Capsules: A Multi-Targeted Therapy for Progressive Medullary Thyroid Cancer
2
Lorlatinib: Mechanism, Advantages, and Key Considerations of Third-Generation ALK Inhibitor Therapy in ALK-Positive NSCLC
3
Pemigatinib Side Effects Explained: Managing Adverse Reactions of FGFR-Targeted Therapy in Cholangiocarcinoma
4
Selpercatinib: Before or After Meals? A Complete Guide to RET-Targeted Therapy Administration
5
Mitotane for Adrenocortical Carcinoma: Dosing Guidelines and Therapeutic Drug Monitoring
6
Leflunomide and Ocular Adverse Effects: Risk Awareness and Clinical Guidance
7
Clinical Management of Acquired Resistance to Garsorasib (KRAS G12C Inhibitor)
8
Chemical Structure of Capivasertib: A Novel AKT Inhibitor
9
Capivasertib: An AKT Inhibitor for Breast and Prostate Cancer
10
Global Update 2026: Selumetinib (KOSELUGO) Expands Indication to Adult NF1-PN and Clinical Management Strategies
11
Lenvatinib Safety Guide: Baseline Assessment & Adverse Reaction Management
12
Inluriyo (Imlunestrant): Oral SERD for ER+/HER2- Breast Cancer with ESR1 Mutations